Inhibidores del SGLT2 y enfermedad renal crónica. Revisión sistemática

Abstract

Background: Chronic kidney disease is a multifactorial pathology causing irreversible deterioration of kidney functionality; making it challenging to treat patients with comorbidities; therefore Sodium-glucose cotransporter-2 (SGLT2) inhibitors have gained favor for administration without evidence of renal damage. Objective: To determine the benefit of SGLT2 inhibitors in chronic kidney disease treatment. Materials and methods: A systematic review of documents from different scientific societies earmarked to studying chronic kidney disease and managing SGLT2 inhibitors will be conducted. In addition, it will be directed to investigate articles from different health institutions on the benefits or risks of SGLT2 inhibitors usage. The information will be organized through the PRISMA 2020 statement, which has 4 phases of selection. Results: The collection of 12 scientific articles in 125 countries with patients aged 50 – 75 shows that SGLT2 inhibitors are a fundamental pillar in treating patients with chronic kidney disease, presenting a 95% CI and probability values lower than P=0.01 in all their analyses. Conclusions: SGLT2 inhibitors provide substantial evidence for use not only as antidiabetic agents, as evidenced in the collected articles, but also for their safety in patients with diverse nephropathies and advanced age groups.